Site of extrahepatic primary cancer | Synchronous group (n = 22) | Metachronous group (n = 46) | Total (n = 68) |
---|---|---|---|
Head & neck | 8 (36.4%) | 15 (32.6%) | 23 (33.8%) |
nasopharynx | 2 (1R 1S) * | 9 (9R) | 11 |
tonsil | 1 (1C) | 0 | 1 |
larynx | 1 (1C) | 0 | 1 |
vocal cord | 1 (1S) | 1 (1O) | 2 |
mouth | 0 | 1 (1O) | 1 |
tongue | 2 (1C1S) | 1 (1O) | 3 |
gingiva | 0 | 1 (1O) | 1 |
soft palate | 1 (1S) | 0 | 1 |
thyroid gland | 0 | 2 (2O) | 2 |
Digestive system | 8 (36.4%) | 10 (21.7%) | 18 (26.5%) |
esophagus | 1 (1S) | 4 (3O1C) | 5 |
stomach | 2 (2O) | 1 (1O) | 3 |
colorectal | 5 (5O) | 5 (5O) | 10 |
Urogenital system | 1 (4.5%) | 5 (10.9%) | 6 (8.8%) |
prostate | 0 | 1 (1O) | 1 |
urinary bladder | 1 (1O) | 1 (1O) | 2 |
kidney | 0 | 2 (1O1C) | 2 |
ovary | 0 | 1 (1O) | 1 |
Others | 5 (22.7%) | 16 (34.8%) | 20 (29.4%) |
lung | 2 (1C1S) | 4 (1O2C 1R) | 6 |
breast | 0 | 4 (4O) | 4 |
skin | 1 (1O) | 4 (4O) | 5 |
Non Hodgkin’s lymphoma | 1 (1R) † | 3 (3C) | 3 |
melanoma | 0 | 1 (1O) | 1 |
Soft tissue tumor | 1 (1O) | 0 | 0 |